menu
    • menu

    Company profile for Bristol Myers Squibb

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Aurigene is a global leader in accelerating drug innovation through discovery, development & manufacturing.

    Virtual Booth

    Contact Supplier

    Midas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-06

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Bristol-Myers Squibb is a differentiated company, led by our unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. We work every day to deliver innovative medicines for patients with serious and life-threatening diseases. Each day, our employees around the world work together for patients – it drives everything we do. ...
    Bristol-Myers Squibb is a differentiated company, led by our unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. We work every day to deliver innovative medicines for patients with serious and life-threatening diseases. Each day, our employees around the world work together for patients – it drives everything we do. We are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Bristol Myers SquibbUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    430 E. 29th Street, 14th Floor, New York, NY 10016
    Telephone
    Telephone
    +1 (212) 546 4000
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.bms.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/bristol-myers-squibb
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/BMSNEWS

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    “Translational Pharmaceutics, our flagship platform for drug development, empowers our clients with unparalleled flexibility”

    “Translational Pharmaceutics, our flagship platform for drug development, empowers our clients with unparalleled flexibility”

    This week, SpeakPharma interviews Denise Sutton, Chief Operating Officer and Site Head at Quotient Sciences’ Nottingham facility in the UK. Quotient Sciences is a drug development and manufacturing accelerator that offers the innovative Translational Pharmaceutics platform to support customers in overcoming drug development challenges. Sutton has been with the company for over 25 years. In this interview, she provides insights into the evolution of Quotient Sciences’ Nottingham facility and discusses how the organization has transformed from a small 10-bed clinic to a comprehensive drug development campus with six GMP suites. She also shares her perspective on the company’s unique approach to integrating drug development services. HIGHLIGHTS// evolution of Quotient Sciences’ Nottingham facility/ unique approach to integrating drug development services How has the Nottingham site transformed from when it was founded, to what it is today? Initially, we were a small company with fewer than 50 employees, a 10-bed clinic, and a single lab. Over 90 percent of our work focused on gamma scintigraphic imaging (a diagnostic test that creates images of the body’s internal organs and tissues using gamma rays). Due to the short half-life radionuclides we used to label dosage forms, every product we manufactured had a limited time to be dosed. At the end of 1999, we moved our headquarters to a purpose-built, two-storey facility—now known as Trent House on our now much larger Nottingham campus. We built three good manufacturing practice (GMP) suites on the top floor and three clinical wards on the bottom floor. These were very early days that marked the start of our Translational Pharmaceutics platform. We continued to expand the range of scintigraphy applications we offered in response to changing customer requirements until, in 2008, when we approached the MHRA (UK’s Medicines and Healthcare products Regulatory Agency) with a new request. We asked if it might be possible to work at the same pace as we did in our scintigraphic imaging studies, but do so for conventional drug development, without the radiolabel. We explored the application of ICH Q8 Quality by Design (QbD) guidelines to introduce a compositional design space into the CMC section of our regulatory dossier. This officially created a methodology for applying the Translational Pharmaceutics platform, and we haven't looked back since. Today, we have expanded substantially. Our Nottingham site is a campus of five buildings. We have development and analytical labs, six GMP suites, six clinical wards with a total of 85 beds (where we conduct healthy volunteer phase 1 clinical studies), and many talented colleagues covering our spectrum of CRO and CDMO services. HIGHLIGHTS// officially created a methodology for applying the Translational Pharmaceutics platform/ development and analytical labs/ six GMP suites   How is Translational Pharmaceutics applied to drug development programs? We apply Translational Pharmaceutics across three core applications: first-in-human clinical studies, drug product optimization programs through rapid formulation development and clinical testing, and as a part of human ADME (absorption, distribution, metabolism, and excretion) programs. No matter how a client chooses to work with us to apply Translational Pharmaceutics, the benefits of using a single organization and project management team to integrate services lets our clients remain in control and one step ahead of the emerging data that impacts the success of their molecule. Over all these years, our flagship Translational Pharmaceutics platform for drug development has remained unchanged in the way it empowers our customers and offers them unparalleled flexibility. HIGHLIGHTS// three core applications/ benefits of using a single organization/ clients remain in control   What would you say are the key strengths of Quotient Sciences’ Nottingham site? How do you support customer programs? Nowhere else would a single project manager oversee such a broad spectrum of activities, let alone be expected to ensure seamless, timely progression across functions that in any other company (i.e. at other CDMOs or CROs) would be delivered through multiple operating areas or through the use of a combination of third-party vendors. The project managers do face challenges. But by working with the project team, they are able to anticipate, avoid, and mitigate any impact whenever necessary. We know that time is incredibly valuable for our customers. A project Gantt chart is our project management team’s guiding light. I believe our project management team is truly world-leading – they communicate well, show great compassion, and lead with integrity. I’m super proud of our high-performing, supportive, cross-functional teams that support our customers when they trust their molecules to us, and work collaboratively to deliver the best possible service. After 25 years at Quotient, I continue to really enjoy going to work. I am indebted to various colleagues for helping me continue to feel this way. HIGHLIGHTS// project management team is truly world-leading/ high-performing, supportive, cross-functional teams/ 25 years at Quotient  

    Impressions: 4916

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/translational-pharmaceutics-our-flagship-platform-for-drug-development-empowers-our-clients-with-unparalleled-flexibility

    Radio Compass
    16 Dec 2024
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    BMS, J&J, Bayer lead 25,000+ pharma layoffs in 2024; Amylyx, FibroGen, Kronos Bio hit by trial failures, cash crunch

    BMS, J&J, Bayer lead 25,000+ pharma layoffs in 2024; Amylyx, FibroGen, Kronos Bio hit by trial failures, cash crunch

    Since 2022, there has been a significant surge in layoffs by pharmaceutical and biotech companies. While this trend continued into 2024, the industry showed signs of stabilization in the last four months of the year with the pace of layoffs slowing down. Nonetheless, 2024 was a challenging year. Data compiled by PharmaCompass indicates that over 25,000 layoffs were announced in 2024, driven by economic pressures, failed clinical trials, and strategic pivots. Bristol Myers Squibb and Johnson & Johnson led the layoffs with about 2,300 job cuts each. Bayer announced elimination of 1,800 positions.  View Our Interactive Dashboard on Biopharma Layoffs in 2024 (Free Excel Available) US, Europe, China bear brunt of job cuts; Big Pharma hands pink slips to 10,000 Over 190 biopharma companies announced layoffs in 2024. The year began on a grim note — 27 firms announced significant job cuts in January 2024. By the yearend, Big Pharma alone had contributed more than 10,000 layoffs to the year’s total of over 25,000. Novartis announced over 1,200 job cuts in 2024. It eliminated 330 jobs after it acquired German biotech MorphoSys through the closure of sites in Munich and Boston. Similarly, Bayer announced significant reductions at its US and Swiss facilities.  North America saw increased retrenchments, especially at biotech hubs such as Boston, San Diego, and New Jersey. Massachusetts, with Boston and Cambridge as the epicenter of US biotechnology, saw around 4,000 layoffs, with companies like Relay Therapeutics, Editas Medicine, and Takeda driving the numbers. In San Diego, workforce reductions by Takeda, and Bavarian Nordic collectively resulted in over 900 job losses, significantly impacting the local biotech ecosystem. New Jersey was subject to broader restructuring efforts with BMS and Bayer contributing nearly 1,500 layoffs. The impact in Europe was equally severe. Germany, home to some of the world’s largest pharmaceutical companies, saw over 2,500 layoffs as Bayer and Boehringer Ingelheim scaled back operations. Novartis’ decision to shut down its Munich site added hundreds more to the tally. In Switzerland, Idorsia eliminated 270 positions. Dutch biotech UniQure reduced its workforce by 65 percent (around 300 jobs). That included the sale of a Massachusetts manufacturing facility to Genezen. Denmark also felt the strain, with Leo Pharma cutting 250 roles as part of a strategic revamp. China emerged as another focal point of workforce reductions in 2024. Global pharmaceutical giants, such as Merck and Johnson & Johnson, restructured their operations in response to market complexities in the region. Local companies such as Connect Biopharma, which is transitioning to a US-focused company, also scaled back their presence in the country.  View Our Interactive Dashboard on Biopharma Layoffs in 2024 (Free Excel Available)  Amylyx, FibroGen, Lyra, Athira drastically reduce staff over setbacks in clinical trials Clinical trial failures were one of the most significant drivers of layoffs in 2024. For instance, Amylyx Pharmaceuticals faced a devastating blow when its amyotrophic lateral sclerosis (ALS) therapy, Relyvrio, failed a confirmatory trial. This led to a 70 percent reduction in its workforce, leaving only 100 employees from the 384 full-time staff reported at the end of 2023. The company’s decision to pull the therapy from the market compounded the layoffs. BioMarin Pharmaceutical had to reduce its workforce, as it streamlined its pipeline in response to trial challenges. In August, the company announced a reduction of 225 employees, citing “organizational redesign efforts”. These layoffs followed 170 redundancies announced earlier in May. FibroGen, once considered a leader in oncology drug development, was among the most heavily impacted. The high-profile failure of its anti-CTGF antibody in two late-stage cancer trials led to the discontinuation of its lead candidate, resulting in a 75 percent reduction in its US workforce. Lyra Therapeutics also implemented a 75 percent workforce reduction, affecting 87 employees, after its chronic rhinosinusitis program struggled. Similarly, Athira Pharma cut 70 percent of its team after its Alzheimer’s candidate failed a phase 2/3 trial.  View Our Interactive Dashboard on Biopharma Layoffs in 2024 (Free Excel Available)  Cash crunch, mergers compel Kronos Bio, Editas, Vincerx, Gilead to downsize In addition to clinical failures, funding constraints played a pivotal role in reshaping the biotech landscape. Kronos Bio stood out as one of the hardest-hit firms, cutting 21 percent and 83 percent of its existing workforce in March and November, respectively, as it sought to divest assets and conserve cash. Editas Medicine’s inability to secure partnerships for its sickle cell program forced the company to revert to preclinical research, resulting in a 65 percent workforce reduction. The trend of scaling back R&D pipelines was particularly evident among biotechs struggling to advance preclinical programs to clinical trials. Boundless Bio and Senti Bio exemplified this, choosing to focus on a handful of promising candidates, while reducing discovery efforts. Consolidation often results in overlapping roles, leading to inevitable workforce reductions. Apart from the MorphoSys layoffs by Novartis, Vincerx Pharma faced job losses after it got acquired by Oqory (a clinical-stage ADC company). Vincerx had to cut its workforce by 55 percent.  Amid ongoing reorganization efforts, Gilead closed its Seattle, Washington (US), office and laid off 72 employees of its subsidiary Kite Pharma. Gilead also announced that its Kite facility in Philadelphia, Pennsylvania (US), would close by mid-2025. That was followed by 104 additional layoffs at its California headquarters. In April, it had cut 58 jobs in California. Gilead also announced that its Kite facility in Philadelphia would close by mid-2025. Vir Biotechnology reduced its workforce by 25 percent (i.e. 140 layoffs) to focus on its hepatitis program, and GlycoMimetics let go of 80 percent of its workforce after the FDA demanded an additional clinical trial for its leukemia treatment. Meanwhile, Lexicon Pharmaceuticals reduced its workforce by 60 percent after it stopped commercial operations and transitioned back to being a clinical stage company.  View Our Interactive Dashboard on Biopharma Layoffs in 2024 (Free Excel Available)  Our view It takes decades to build innovation ecosystems. The concentration of layoffs in major biotech hubs has raised concerns about the potential long-term impact on these ecosystems. In 2025, the key challenge will be to maintain the momentum of innovation, as organizations operate with a leaner workforce and a more focused pipeline.  
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 4560

    https://www.pharmacompass.com/radio-compass-blog/bms-j-j-bayer-lead-25-000-pharma-layoffs-in-2024-amylyx-fibrogen-kronos-bio-hit-by-trial-failures-cash-crunch

    #PharmaFlow by PHARMACOMPASS
    16 Jan 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    BMS Named to Dow Jones Sustainability Index North America
    BMS Named to Dow Jones Sustainability Index North America

    10 Jan 2025

    // ACCESSWIRE

    https://www.accesswire.com/966855/bristol-myers-squibb-named-to-dow-jones-sustainability-index-north-america-for-second-consecutive-year

    ACCESSWIRE
    10 Jan 2025
    Share Share
    BMS to Present at J.P. Morgan’s 43rd Annual Healthcare Conference
    BMS to Present at J.P. Morgan’s 43rd Annual Healthcare Conference

    03 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250103085178/en

    BUSINESSWIRE
    03 Jan 2025
    Share Share
    FDA approves BMS' subcutaneous Opdivo with some limitations
    FDA approves BMS' subcutaneous Opdivo with some limitations

    02 Jan 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/bristol-myers-celebrates-10-years-opdivo-fda-approval-subcutaneous-version

    FIERCE PHARMA
    02 Jan 2025
    Share Share
    BMS secures subcutaneous Opdivo approval
    BMS secures subcutaneous Opdivo approval

    28 Dec 2024

    // FDA

    https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-and-hyaluronidase-nvhy-subcutaneous-injection

    FDA
    28 Dec 2024
    Share Share
    BMS`s Biologic Opdivo Qvantig Receives Approval in US
    BMS`s Biologic Opdivo Qvantig Receives Approval in US

    27 Dec 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761429

    FDA
    27 Dec 2024
    Share Share
    Sotyktu has excelled in 2 psoriatic arthritis trials, BMS says
    Sotyktu has excelled in 2 psoriatic arthritis trials, BMS says

    26 Dec 2024

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/trial-results-pave-way-bristol-myers-squibbs-struggling-sotyktu-gain-potential-approval

    FIERCE PHARMA
    26 Dec 2024
    Share Share

    ALL APIs

    read-moreClick the button for full data set
    read-moreClick the button for full data set

    01

    Tremelimumab

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Biotech Showcase
    Not Confirmed
    arrow

    Tremelimumab

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Biotech Showcase
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down Click Us! arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 19512

    Submission : 2005-08-23

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    6-Aminopenicillanic Acid

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Biotech Showcase
    Not Confirmed
    arrow

    6-Aminopenicillanic Acid

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Biotech Showcase
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 10139

    Submission : 1968-06-10

    Status : Inactive

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    7-Amino Cephalosporanic Acid

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Biotech Showcase
    Not Confirmed
    arrow

    7-Amino Cephalosporanic Acid

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Biotech Showcase
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 10132

    Submission : 1989-06-20

    Status : Inactive

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    7-Aminodesacetoxycephalosporanic Ac...

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Biotech Showcase
    Not Confirmed
    arrow

    7-Aminodesacetoxycephalosporanic Ac...

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Biotech Showcase
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 10155

    Submission : 1974-08-27

    Status : Inactive

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Amphotericin B

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Biotech Showcase
    Not Confirmed
    arrow

    Amphotericin B

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Biotech Showcase
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 10126

    Submission : 1987-06-26

    Status : Inactive

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Piperacillin Sodium

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Biotech Showcase
    Not Confirmed
    arrow

    Piperacillin Sodium

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Biotech Showcase
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 10133

    Submission : 1982-02-02

    Status : Inactive

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Triamcinolone Diacetate

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Biotech Showcase
    Not Confirmed
    arrow

    Triamcinolone Diacetate

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Biotech Showcase
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 11349

    Submission : 1995-02-14

    Status : Inactive

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    PATIENT STARTER PACKAGES

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Biotech Showcase
    Not Confirmed
    arrow

    PATIENT STARTER PACKAGES

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Biotech Showcase
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 1014

    Submission : 1966-12-14

    Status : Inactive

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    LISTING OF INDS

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Biotech Showcase
    Not Confirmed
    arrow

    LISTING OF INDS

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Biotech Showcase
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 1033

    Submission : 1966-03-10

    Status : Inactive

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    MANUFACTURE OF HYDROXYUREA

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Biotech Showcase
    Not Confirmed
    arrow

    MANUFACTURE OF HYDROXYUREA

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Biotech Showcase
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 1077

    Submission : 1967-08-25

    Status : Inactive

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    USDMF

    read-more
    read-more

    01

    6-apa

    U.S.A
    BIO Partnering at JPM
    Not Confirmed
    arrow

    02

    7-adca

    U.S.A
    BIO Partnering at JPM
    Not Confirmed
    arrow

    03

    7-amino Cephalosporanic Acid (7-aca)

    U.S.A
    BIO Partnering at JPM
    Not Confirmed
    arrow

    04

    Amikacin Base

    U.S.A
    BIO Partnering at JPM
    Not Confirmed
    arrow

    05

    Amikacin Sulfate

    U.S.A
    BIO Partnering at JPM
    Not Confirmed
    arrow

    06

    Amoxicillin Trihydrate

    U.S.A
    BIO Partnering at JPM
    Not Confirmed
    arrow

    07

    Amphotericin B

    U.S.A
    BIO Partnering at JPM
    Not Confirmed
    arrow

    08

    Amphotericin Non Parental Grade

    U.S.A
    BIO Partnering at JPM
    Not Confirmed
    arrow

    09

    Ampicillin

    U.S.A
    BIO Partnering at JPM
    Not Confirmed
    arrow

    10

    Ampicillin Sodium

    U.S.A
    BIO Partnering at JPM
    Not Confirmed
    arrow
    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    BioArctic Licenses PyroGlutamate-Aβ Antibody Program To Bristol Myers Squibb Globally

    Details:

    Under the license agreement, BMS will become solely responsible for the development and any subsequent commercialization of BAN1503, which is being evaluated for Alzheimer Disease.


    Lead Product(s): BAN1503

    Therapeutic Area: Neurology Brand Name: BAN1503

    Study Phase: PreclinicalProduct Type: Large molecule

    Recipient: BioArctic AB

    Deal Size: $1,125.0 million Upfront Cash: $100.0 million

    Deal Type: Licensing Agreement December 19, 2024

    blank

    01

    Bristol Myers Squibb

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Bristol Myers Squibb

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : BAN1503

    Therapeutic Area : Neurology

    Highest Development Status : Preclinical

    Recipient : BioArctic AB

    Deal Size : $1,125.0 million

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    BioArctic Licenses PyroGlutamate-Aβ Antibody Program To Bristol Myers Squibb Globally

    Details : Under the license agreement, BMS will become solely responsible for the development and any subsequent commercialization of BAN1503, which is being evaluated for Alzheimer Disease.

    Brand Name : BAN1503

    Molecule Type : Large molecule

    Upfront Cash : $100.0 million

    December 19, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Insitro Gains $25 Million From BMS Milestones in ALS Genetic Target Discovery

    Details:

    The companies signed a collaboration agreement to discover new therapies for the treatment of myotrophic lateral sclerosis .


    Lead Product(s): C&G Therapy

    Therapeutic Area: Neurology Brand Name: Undisclosed

    Study Phase: DiscoveryProduct Type: Cell and Gene therapy

    Recipient: Insitro

    Deal Size: $2,075.0 million Upfront Cash: $50.0 million

    Deal Type: Collaboration December 18, 2024

    blank

    02

    Bristol Myers Squibb

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Bristol Myers Squibb

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : C&G Therapy

    Therapeutic Area : Neurology

    Highest Development Status : Discovery

    Recipient : Insitro

    Deal Size : $2,075.0 million

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Insitro Gains $25 Million From BMS Milestones in ALS Genetic Target Discovery

    Details : The companies signed a collaboration agreement to discover new therapies for the treatment of myotrophic lateral sclerosis .

    Brand Name : Undisclosed

    Molecule Type : Cell and Gene therapy

    Upfront Cash : $50.0 million

    December 18, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Bristol Myers Squibb Taps AI Proteins in Drug Discovery Collaboration Worth Up to $400M

    Details:

    Under the collaboration, AI Proteins will leverage its proprietary AI-driven platform to design and optimize novel miniprotein-based therapeutics against targets of interest to Bristol Myers Squibb.


    Lead Product(s): Miniprotein-Based Therapeutics

    Therapeutic Area: Technology Brand Name: Undisclosed

    Study Phase: Discovery PlatformProduct Type: Large molecule

    Recipient: AI Proteins

    Deal Size: $400.0 million Upfront Cash: Undisclosed

    Deal Type: Collaboration December 03, 2024

    blank

    03

    Bristol Myers Squibb

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Bristol Myers Squibb

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Miniprotein-Based Therapeutics

    Therapeutic Area : Technology

    Highest Development Status : Discovery Platform

    Recipient : AI Proteins

    Deal Size : $400.0 million

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Bristol Myers Squibb Taps AI Proteins in Drug Discovery Collaboration Worth Up to $400M

    Details : Under the collaboration, AI Proteins will leverage its proprietary AI-driven platform to design and optimize novel miniprotein-based therapeutics against targets of interest to Bristol Myers Squibb.

    Brand Name : Undisclosed

    Molecule Type : Large molecule

    Upfront Cash : Undisclosed

    December 03, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    BMS Gains CHMP Nod for Opdivo® + Yervoy® in MSI-High Colorectal Cancer

    Details:

    Opdivo (nivolumab) in combination with Yervoy (ipilimumab) is being evaluated for the treatment of microsatellite instability–high or mismatch repair deficient metastatic colorectal cancer.


    Lead Product(s): Nivolumab,Ipilimumab

    Therapeutic Area: Oncology Brand Name: Opdivo

    Study Phase: ApprovedProduct Type: Large molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 15, 2024

    blank

    04

    Bristol Myers Squibb

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Bristol Myers Squibb

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Nivolumab,Ipilimumab

    Therapeutic Area : Oncology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    BMS Gains CHMP Nod for Opdivo® + Yervoy® in MSI-High Colorectal Cancer

    Details : Opdivo (nivolumab) in combination with Yervoy (ipilimumab) is being evaluated for the treatment of microsatellite instability–high or mismatch repair deficient metastatic colorectal cancer.

    Brand Name : Opdivo

    Molecule Type : Large molecule

    Upfront Cash : Not Applicable

    November 15, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Bristol Myers Receives CHMP Opinion for Repotrectinib in ROS1/NTRK Tumors

    Details:

    Augtyro (repotrectinib) is a next-generation tyrosine kinase inhibitor (TKI), for the treatment of locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).


    Lead Product(s): Repotrectinib

    Therapeutic Area: Oncology Brand Name: Augtyro

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 15, 2024

    blank

    05

    Bristol Myers Squibb

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Bristol Myers Squibb

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Repotrectinib

    Therapeutic Area : Oncology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Bristol Myers Receives CHMP Opinion for Repotrectinib in ROS1/NTRK Tumors

    Details : Augtyro (repotrectinib) is a next-generation tyrosine kinase inhibitor (TKI), for the treatment of locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).

    Brand Name : Augtyro

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    November 15, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Redwire And Bristol Myers Study Bone Disease Treatments in Space

    Details:

    The partnership aims to study model small molecule compounds, including ELP-004, using Redwire’s pharmaceutical drug development platform (PIL-BOX).


    Lead Product(s): ELP-004

    Therapeutic Area: Orthopedics/Orthopedic Surgery Brand Name: ELP-004

    Study Phase: PreclinicalProduct Type: Small molecule

    Recipient: Redwire Corporation

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership October 23, 2024

    blank

    06

    Bristol Myers Squibb

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Bristol Myers Squibb

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : ELP-004

    Therapeutic Area : Orthopedics/Orthopedic Surgery

    Highest Development Status : Preclinical

    Recipient : Redwire Corporation

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    Redwire And Bristol Myers Study Bone Disease Treatments in Space

    Details : The partnership aims to study model small molecule compounds, including ELP-004, using Redwire’s pharmaceutical drug development platform (PIL-BOX).

    Brand Name : ELP-004

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    October 23, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Prime Medicine and Bristol Myers Partner On Ex Vivo T-Cell Therapies

    Details:

    The collaboration combines Prime Medicine’s precise, multiplex gene editing capabilities with BMS’s broad expertise in development and commercialization of novel ex vivo T-cell therapies.


    Lead Product(s): T-Cell Therapy

    Therapeutic Area: Hematology Brand Name: Undisclosed

    Study Phase: PreclinicalProduct Type: Cell and Gene therapy

    Recipient: Prime Medicine

    Deal Size: $3,610.0 million Upfront Cash: Undisclosed

    Deal Type: Collaboration September 30, 2024

    blank

    07

    Bristol Myers Squibb

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Bristol Myers Squibb

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : T-Cell Therapy

    Therapeutic Area : Hematology

    Highest Development Status : Preclinical

    Recipient : Prime Medicine

    Deal Size : $3,610.0 million

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Prime Medicine and Bristol Myers Partner On Ex Vivo T-Cell Therapies

    Details : The collaboration combines Prime Medicine’s precise, multiplex gene editing capabilities with BMS’s broad expertise in development and commercialization of novel ex vivo T-cell therapies.

    Brand Name : Undisclosed

    Molecule Type : Cell and Gene therapy

    Upfront Cash : Undisclosed

    September 30, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    BMS Pays Prime $110M to Form T-cell Therapy Pact

    Details:

    Prime Medicine will design optimized Prime Editor reagents for a select number of targets, including reagents that use its Prime Assisted Site-Specific Integrase Gene Editing (PASSIGE™) technology.


    Lead Product(s): T-Cell-based Therapy

    Therapeutic Area: Hematology Brand Name: Undisclosed

    Study Phase: PreclinicalProduct Type: Cell and Gene therapy

    Recipient: Prime Medicine

    Deal Size: $3,610.0 million Upfront Cash: $110.0 million

    Deal Type: Collaboration September 30, 2024

    blank

    08

    Bristol Myers Squibb

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Bristol Myers Squibb

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : T-Cell-based Therapy

    Therapeutic Area : Hematology

    Highest Development Status : Preclinical

    Recipient : Prime Medicine

    Deal Size : $3,610.0 million

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    BMS Pays Prime $110M to Form T-cell Therapy Pact

    Details : Prime Medicine will design optimized Prime Editor reagents for a select number of targets, including reagents that use its Prime Assisted Site-Specific Integrase Gene Editing (PASSIGE™) technology.

    Brand Name : Undisclosed

    Molecule Type : Cell and Gene therapy

    Upfront Cash : $110.0 million

    September 30, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Bristol Myers Shows Sotyktu Efficacy in Scalp Psoriasis And Real-World Data

    Details:

    Sotyktu (deucravacitinib) is an oral, selective, allosteric TYK2 inhibitor. It inhibits the signaling of IL-23/12 and Type 1 IFN, cytokines involved in the pathogenesis of immune-mediated diseases.


    Lead Product(s): Deucravacitinib

    Therapeutic Area: Dermatology Brand Name: Sotyktu

    Study Phase: Phase IVProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 27, 2024

    blank

    09

    Bristol Myers Squibb

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Bristol Myers Squibb

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Deucravacitinib

    Therapeutic Area : Dermatology

    Highest Development Status : Phase IV

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Bristol Myers Shows Sotyktu Efficacy in Scalp Psoriasis And Real-World Data

    Details : Sotyktu (deucravacitinib) is an oral, selective, allosteric TYK2 inhibitor. It inhibits the signaling of IL-23/12 and Type 1 IFN, cytokines involved in the pathogenesis of immune-mediated diseases.

    Brand Name : Sotyktu

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    September 27, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Schizophrenia Space Anticipates First-in-Class FDA Approval for BMS’ KarXT

    Details:

    Cobenfy (xanomeline-trospium) is an oral, investigational M1/M4 agonist indcated for psychiatric and neurological conditions, including schizophrenia.


    Lead Product(s): Xanomeline,Trospium

    Therapeutic Area: Psychiatry/Psychology Brand Name: Cobenfy

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 26, 2024

    blank

    10

    Bristol Myers Squibb

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Bristol Myers Squibb

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Xanomeline,Trospium

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Schizophrenia Space Anticipates First-in-Class FDA Approval for BMS’ KarXT

    Details : Cobenfy (xanomeline-trospium) is an oral, investigational M1/M4 agonist indcated for psychiatric and neurological conditions, including schizophrenia.

    Brand Name : Cobenfy

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    September 26, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    FDA Orange Book

    read-more
    read-more

    01

    Brand Name : ORENCIA

    U.S.A
    BIO Partnering at JPM
    Not Confirmed
    arrow

    Brand Name : ORENCIA

    U.S.A
    BIO Partnering at JPM
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    RLD :

    TE Code :

    ABATACEPT

    Bristol Myers Squibb

    Dosage Form : INJECTABLE; IV (INFUSION)

    Proprietary Name : ORENCIA

    Dosage Strength : 250MG

    Approval Date :

    Application Number : 125118

    RX/OTC/DISCN :

    RLD :

    TE Code :

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Brand Name : OXYCODONE 2.5/APAP 5...

    U.S.A
    BIO Partnering at JPM
    Not Confirmed
    arrow

    Brand Name : OXYCODONE 2.5/APAP 5...

    U.S.A
    BIO Partnering at JPM
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    RLD : No

    TE Code :

    ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

    Bristol Myers Squibb

    Dosage Form : TABLET; ORAL

    Proprietary Name : OXYCODONE 2.5/APAP 500

    Dosage Strength : 500MG;2.5MG

    Approval Date : 1982-01-01

    Application Number : 85910

    RX/OTC/DISCN : DISCN

    RLD : No

    TE Code :

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Brand Name : OXYCODONE 5/APAP 500

    U.S.A
    BIO Partnering at JPM
    Not Confirmed
    arrow

    Brand Name : OXYCODONE 5/APAP 500

    U.S.A
    BIO Partnering at JPM
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    RLD : No

    TE Code :

    ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

    Bristol Myers Squibb

    Dosage Form : TABLET; ORAL

    Proprietary Name : OXYCODONE 5/APAP 500

    Dosage Strength : 500MG;5MG

    Approval Date : 1982-01-01

    Application Number : 85911

    RX/OTC/DISCN : DISCN

    RLD : No

    TE Code :

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Brand Name : MUCOMYST

    U.S.A
    BIO Partnering at JPM
    Not Confirmed
    arrow

    Brand Name : MUCOMYST

    U.S.A
    BIO Partnering at JPM
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    RLD : Yes

    TE Code :

    ACETYLCYSTEINE

    Bristol Myers Squibb

    Dosage Form : SOLUTION; INHALATION, ORAL

    Proprietary Name : MUCOMYST

    Dosage Strength : 20% **Federal Register d...

    Approval Date : 1982-01-01

    Application Number : 13601

    RX/OTC/DISCN : DISCN

    RLD : Yes

    TE Code :

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Brand Name : MUCOMYST

    U.S.A
    BIO Partnering at JPM
    Not Confirmed
    arrow

    Brand Name : MUCOMYST

    U.S.A
    BIO Partnering at JPM
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    RLD : Yes

    TE Code :

    ACETYLCYSTEINE

    Bristol Myers Squibb

    Dosage Form : SOLUTION; INHALATION, ORAL

    Proprietary Name : MUCOMYST

    Dosage Strength : 10% **Federal Register d...

    Approval Date : 1982-01-01

    Application Number : 13601

    RX/OTC/DISCN : DISCN

    RLD : Yes

    TE Code :

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Brand Name : ACYCLOVIR SODIUM

    U.S.A
    BIO Partnering at JPM
    Not Confirmed
    arrow

    Brand Name : ACYCLOVIR SODIUM

    U.S.A
    BIO Partnering at JPM
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    RLD : No

    TE Code :

    ACYCLOVIR SODIUM

    Bristol Myers Squibb

    Dosage Form : INJECTABLE; INJECTION

    Proprietary Name : ACYCLOVIR SODIUM

    Dosage Strength : EQ 500MG BASE/VIAL

    Approval Date : 1998-02-27

    Application Number : 74897

    RX/OTC/DISCN : DISCN

    RLD : No

    TE Code :

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Brand Name : ACYCLOVIR SODIUM

    U.S.A
    BIO Partnering at JPM
    Not Confirmed
    arrow

    Brand Name : ACYCLOVIR SODIUM

    U.S.A
    BIO Partnering at JPM
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    RLD : No

    TE Code :

    ACYCLOVIR SODIUM

    Bristol Myers Squibb

    Dosage Form : INJECTABLE; INJECTION

    Proprietary Name : ACYCLOVIR SODIUM

    Dosage Strength : EQ 1GM BASE/VIAL

    Approval Date : 1998-02-27

    Application Number : 74897

    RX/OTC/DISCN : DISCN

    RLD : No

    TE Code :

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    Brand Name : AMIKIN

    U.S.A
    BIO Partnering at JPM
    Not Confirmed
    arrow

    Brand Name : AMIKIN

    U.S.A
    BIO Partnering at JPM
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    RLD : Yes

    TE Code :

    AMIKACIN SULFATE

    Bristol Myers Squibb

    Dosage Form : INJECTABLE; INJECTION

    Proprietary Name : AMIKIN

    Dosage Strength : EQ 50MG BASE/ML **Federa...

    Approval Date : 1982-01-01

    Application Number : 50495

    RX/OTC/DISCN : DISCN

    RLD : Yes

    TE Code :

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    Brand Name : AMIKIN

    U.S.A
    BIO Partnering at JPM
    Not Confirmed
    arrow

    Brand Name : AMIKIN

    U.S.A
    BIO Partnering at JPM
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    RLD : Yes

    TE Code :

    AMIKACIN SULFATE

    Bristol Myers Squibb

    Dosage Form : INJECTABLE; INJECTION

    Proprietary Name : AMIKIN

    Dosage Strength : EQ 250MG BASE/ML **Feder...

    Approval Date : 1982-01-01

    Application Number : 50495

    RX/OTC/DISCN : DISCN

    RLD : Yes

    TE Code :

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    Brand Name : AMIKIN

    U.S.A
    BIO Partnering at JPM
    Not Confirmed
    arrow

    Brand Name : AMIKIN

    U.S.A
    BIO Partnering at JPM
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    RLD : No

    TE Code :

    AMIKACIN SULFATE

    Bristol Myers Squibb

    Dosage Form : INJECTABLE; INJECTION

    Proprietary Name : AMIKIN

    Dosage Strength : EQ 50MG BASE/ML

    Approval Date : 1984-09-20

    Application Number : 62562

    RX/OTC/DISCN : DISCN

    RLD : No

    TE Code :

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view

    Excipients

    Click here to find the perfect excipient manufacturers by their capabilities

    All Excipients

    read-more
    read-more

    01

    PLASTIBASE 50W

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    BIO Partnering at JPM
    Not Confirmed
    arrow

    PLASTIBASE 50W

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down Click Us! arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 10925

    Submission : 1994-05-25

    Status : Active

    Type : IV

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    SILICONE FLUIDS

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    BIO Partnering at JPM
    Not Confirmed
    arrow

    SILICONE FLUIDS

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 893

    Submission : 1965-05-13

    Status : Inactive

    Type : IV

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    PLASTIBASE (SQUIBB PLASTICIZED HYDR...

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    BIO Partnering at JPM
    Not Confirmed
    arrow

    PLASTIBASE (SQUIBB PLASTICIZED HYDR...

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 1098

    Submission : 1967-11-17

    Status : Inactive

    Type : IV

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    PLACEBO FOR FLUPHENAZINE HCL TABLET...

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    BIO Partnering at JPM
    Not Confirmed
    arrow

    PLACEBO FOR FLUPHENAZINE HCL TABLET...

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 3512

    Submission : 1979-01-18

    Status : Inactive

    Type : IV

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    PLASTIBASE 10W (PLASTICIZED HYDROCA...

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    BIO Partnering at JPM
    Not Confirmed
    arrow

    PLASTIBASE 10W (PLASTICIZED HYDROCA...

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 11468

    Submission : 1995-04-20

    Status : Inactive

    Type : IV

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    USDMF

    read-more
    read-more

    01

    PLACEBO FOR FLUPHENAZINE HCL...

    BIO Partnering at JPM
    Not Confirmed
    arrow

    PLACEBO FOR FLUPHENAZINE HCL...

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Bristol Myers Squibb

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 3512

    Submission : 1979-01-18

    Status : Inactive

    Type : IV

    blank

    Excipients Web Link

    Market Place

    02

    PLASTIBASE (SQUIBB PLASTICIZ...

    BIO Partnering at JPM
    Not Confirmed
    arrow

    PLASTIBASE (SQUIBB PLASTICIZ...

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Bristol Myers Squibb

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 1098

    Submission : 1967-11-17

    Status : Inactive

    Type : IV

    blank

    Excipients Web Link

    Market Place

    03

    PLASTIBASE 10W (PLASTICIZED ...

    BIO Partnering at JPM
    Not Confirmed
    arrow

    PLASTIBASE 10W (PLASTICIZED ...

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Bristol Myers Squibb

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 11468

    Submission : 1995-04-20

    Status : Inactive

    Type : IV

    blank

    Excipients Web Link

    Market Place

    04

    PLASTIBASE 50W

    BIO Partnering at JPM
    Not Confirmed
    arrow

    PLASTIBASE 50W

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Bristol Myers Squibb

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 10925

    Submission : 1994-05-25

    Status : Active

    Type : IV

    blank

    Excipients Web Link

    Market Place

    05

    SILICONE FLUIDS

    BIO Partnering at JPM
    Not Confirmed
    arrow

    SILICONE FLUIDS

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Bristol Myers Squibb

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 893

    Submission : 1965-05-13

    Status : Inactive

    Type : IV

    blank

    Excipients Web Link

    Market Place

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Bristol Myers Squibb and get a quotation

    Bristol Myers Squibb is a supplier offers 89 products (APIs, Excipients or Intermediates).

    Find a price of Tremelimumab bulk with DMF offered by Bristol Myers Squibb

    Find a price of 6-Aminopenicillanic Acid bulk offered by Bristol Myers Squibb

    Find a price of 7-Amino Cephalosporanic Acid bulk offered by Bristol Myers Squibb

    Find a price of 7-Aminodesacetoxycephalosporanic Acid bulk offered by Bristol Myers Squibb

    Find a price of Amikacin bulk offered by Bristol Myers Squibb

    Find a price of Amikacin Sulfate bulk offered by Bristol Myers Squibb

    Find a price of Amoxicillin Trihydrate bulk offered by Bristol Myers Squibb

    Find a price of Amphotericin B bulk offered by Bristol Myers Squibb

    Find a price of Ampicillin bulk offered by Bristol Myers Squibb

    Find a price of Ampicillin Sodium bulk offered by Bristol Myers Squibb

    Find a price of Ampicillin Trihydrate bulk offered by Bristol Myers Squibb

    Find a price of Aripiprazole bulk offered by Bristol Myers Squibb

    Find a price of Benzylpenicillin Sodium bulk offered by Bristol Myers Squibb

    Find a price of Calcium Amphomycin bulk offered by Bristol Myers Squibb

    Find a price of Carmustine bulk offered by Bristol Myers Squibb

    Find a price of Cefaclor bulk offered by Bristol Myers Squibb

    Find a price of Cefadroxil bulk offered by Bristol Myers Squibb

    Find a price of Cefazolin Sodium bulk offered by Bristol Myers Squibb

    Find a price of Cephalexin bulk offered by Bristol Myers Squibb

    Find a price of Cephapirin Sodium bulk offered by Bristol Myers Squibb

    Find a price of Cephradine bulk offered by Bristol Myers Squibb

    Find a price of Cloxacillin Sodium bulk offered by Bristol Myers Squibb

    Find a price of Desonide bulk offered by Bristol Myers Squibb

    Find a price of Diethylstilbestrol bulk offered by Bristol Myers Squibb

    Find a price of Dimetridazol bulk offered by Bristol Myers Squibb

    Find a price of Enoxacin bulk offered by Bristol Myers Squibb

    Find a price of Fluphenazine bulk offered by Bristol Myers Squibb

    Find a price of Fluphenazine Decanoate bulk offered by Bristol Myers Squibb

    Find a price of Glucosamine Hydrochloride bulk offered by Bristol Myers Squibb

    Find a price of Halcinonide bulk offered by Bristol Myers Squibb

    Find a price of Hetacillin bulk offered by Bristol Myers Squibb

    Find a price of Hetacillin Potassium bulk offered by Bristol Myers Squibb

    Find a price of Hydroxyurea bulk offered by Bristol Myers Squibb

    Find a price of Insulin bulk offered by Bristol Myers Squibb

    Find a price of Irbesartan bulk offered by Bristol Myers Squibb

    Find a price of Isoniazid bulk offered by Bristol Myers Squibb

    Find a price of Kanamycin Sulfate bulk offered by Bristol Myers Squibb

    Find a price of Methicillin bulk offered by Bristol Myers Squibb

    Find a price of Nystatin bulk offered by Bristol Myers Squibb

    Find a price of Oxacillin Sodium bulk offered by Bristol Myers Squibb

    Find a price of Penicillin G Potassium bulk offered by Bristol Myers Squibb

    Find a price of Penicillin V Potassium bulk offered by Bristol Myers Squibb

    Find a price of Pentamidine Isethionate bulk offered by Bristol Myers Squibb

    Find a price of Piperacillin Sodium bulk offered by Bristol Myers Squibb

    Find a price of Piperazine bulk offered by Bristol Myers Squibb

    Find a price of Sodium Dicloxacillin bulk offered by Bristol Myers Squibb

    Find a price of Tetracycline Hydrochloride bulk offered by Bristol Myers Squibb

    Find a price of Tipredane bulk offered by Bristol Myers Squibb

    Find a price of Triamcinolone Acetonide bulk offered by Bristol Myers Squibb

    Find a price of Triamcinolone Diacetate bulk offered by Bristol Myers Squibb

    Find a price of Triamcinolone Hexacetonide bulk offered by Bristol Myers Squibb

    Find a price of Triflupromazine bulk offered by Bristol Myers Squibb

    Find a price of Vitamin B12 bulk offered by Bristol Myers Squibb

    Find a price of Warfarin Sodium bulk offered by Bristol Myers Squibb

    Find a price of MDX-1100 (ANTI-CXCL 10/ANTI-IP-10 HUMAN MONOCLONAL ANTIBODY) bulk offered by Bristol Myers Squibb

    Find a price of MDX-015 (ANTI-IL15 HUMAN MONOCLONAL ANTIBODY) bulk offered by Bristol Myers Squibb

    Find a price of MFG. ANALYTICAL SPECS. & METHODS OF ANALYSIS FOR MEL B (ARSOBAL) bulk offered by Bristol Myers Squibb

    Find a price of PERSONNEL FOR PUERTO RICO PLANTS bulk offered by Bristol Myers Squibb

    Find a price of FORMULAS: RHODIAL & BOUQUET 5886 bulk offered by Bristol Myers Squibb

    Find a price of PATIENT STARTER PACKAGES bulk offered by Bristol Myers Squibb

    Find a price of HUMAN MONOCLONAL ANTIBODY (MDX-067) TO HEPARANASE bulk offered by Bristol Myers Squibb

    Find a price of FACILITIES AND CONTROLS PERSONNEL FOR MANUFACTURE AND CONTROL bulk offered by Bristol Myers Squibb

    Find a price of FACILITIES LOCATED IN BARCELONETA, PUERTO RICO - PREVIOUSLY AN ANTIBIOTIC FILE bulk offered by Bristol Myers Squibb

    Find a price of HUMAN MONOCLONAL ANTIBODY (MDX-060) TO CD30 bulk offered by Bristol Myers Squibb

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES. bulk offered by Bristol Myers Squibb

    Find a price of MURINE MONOCLONAL ANTIBODY (PM-81) TO HUMAN MYELOID DIFFERENTIATION ANTIGEN bulk offered by Bristol Myers Squibb

    Find a price of TESTOLACTONE TABLETS, 250 MG bulk offered by Bristol Myers Squibb

    Find a price of PICCOLITE RESIN S 115 L bulk offered by Bristol Myers Squibb

    Find a price of BIS (2-HYDROXY-5-CHLORO PHENYL) SULFIDE bulk offered by Bristol Myers Squibb

    Find a price of MANUFACTURE OF HYDROXYUREA bulk offered by Bristol Myers Squibb

    Find a price of COMPOUND SQ 21, 286 bulk offered by Bristol Myers Squibb

    Find a price of TESTING FACILITIES FOR RAW MATERIALS & FINISHED GOODS bulk offered by Bristol Myers Squibb

    Find a price of HUMAN MONOCLONAL ANTIBODY (MDX-214) TO THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) bulk offered by Bristol Myers Squibb

    Find a price of FACILITIES FOR THE MFG. OF SEMISOLIDS IN HUMACAO, PUERTO RICO bulk offered by Bristol Myers Squibb

    Find a price of FACILITIES LOCATED IN MAYAGUEZ, PUERTO RICO bulk offered by Bristol Myers Squibb

    Find a price of MURINE MONOCLONAL ANTIBODY (ALPHA CTLA4) TOCTLA4 bulk offered by Bristol Myers Squibb

    Find a price of MDX-1303 VALORTIM (TM), ANTI-BACILLUS ANTHRACIS PROTECTIVE ANTIGEN HUMAN MONOCLONAL ANTIBODY bulk offered by Bristol Myers Squibb

    Find a price of PROLIXIN ELIXIR (FLUPHENAZINE HYDROCHLORIDE) bulk offered by Bristol Myers Squibb

    Find a price of JM-9 FOR INJECTION bulk offered by Bristol Myers Squibb

    Find a price of POT. MELARSONYL-mel W (TRIMELARSAN)-MFG, SPECS, & METH. OF ANALYSIS bulk offered by Bristol Myers Squibb

    Find a price of HYDROCHLORIDE 6484 R.P. (VET MED) bulk offered by Bristol Myers Squibb

    Find a price of PLASTIC CONTAINERS bulk offered by Bristol Myers Squibb

    Find a price of LISTING OF INDS bulk offered by Bristol Myers Squibb

    Find a price of DROCINONIDE PHOSPHATE POTASSIUM bulk offered by Bristol Myers Squibb

    Find a price of SUMMARIES OF THE BACKGROUND & QUALIFICATION OF INVEST & MONITORS bulk offered by Bristol Myers Squibb

    Find a price of TRI-BUFFERED BUFFERIN bulk offered by Bristol Myers Squibb

    Find a price of HUMAN MONOCLONAL ANTIBODY (MDX-070) TO PROSTATE SPECIFIC MEMBRANE ANTIGEN bulk offered by Bristol Myers Squibb

    Find a price of METHODS, FACILITIES, AND CONTROLS IN MAYAGUEZ, PUERTO RICO bulk offered by Bristol Myers Squibb

    Find a price of RICIN CONJUGATED MURINE MONOCLONAL ANTIBODY (MDX-RA) TO HUMAN LENS EPITHELIAL CELLS bulk offered by Bristol Myers Squibb

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search